Table 1.

Demographics of recruited patients with Crohn’s disease and ulcerative colitis.

Variable	CD [n = 35]	UC [n = 15]	p-value
Gender			0.849 [overall chi 2 ]
Male	13 [37%]	6 [40%]	0.849 [Z test]
Female	22 [63%]	9 [60%]	0.849 [Z test]
Age at operation [years]	36.9 ± 2.27	37.8 ± 3.10	0.814 [t test]
Age at diagnosis [years]	29.7 ± 2.05	35.3 ± 3.99	0.228 [t test]
Disease duration [months]	91.1 ± 16.11	63.6 ± 22.19	0.779 [t test]
Family history			0.198 [overall chi 2 ]
Yes	11 [31%]	3 [20%]	0.412 [Z test]
No	17 [49%]	12 [80%]	0.039 [Z test]
Data not available	7 [20%]	0 [0%]	0.061 [Z test]
Smoking status			0.779 [overall chi 2 ]
Active/history	22 [63%]	10 [59%]	0.281 [Z test]
Non-smoker	13 [37%]	7 [41%]	0.281 [Z test]
Operation type
Ileocolic resection	20 [57%]	N/A	N/A
Ileocolic resection + other	1 [3%]	N/A	N/A
Ileocolic resection + defunction	1 [3%]	N/A	N/A
Small bowel resection	2 [6%]	N/A	N/A
Sigmoid colectomy	1 [3%]	N/A	N/A
Panproctocolectomy	2 [6%]	N/A	N/A
Washout	1 [3%]	N/A	N/A
Adhesiolysis	1 [3%]	N/A	N/A
Defunction	6 [16%]	N/A	N/A
Total colectomy	N/A	11 [69%]	N/A
Completion proctecomy	N/A	5 [31%]	N/A
Medications at time of surgery	28 [80%]	13 [77%]	0.925 [overall chi 2 ]
Aminosalicylates	9 [26%]	7 [41%]	0.222 [chi2 test]
Steroid	14 [40%]	6 [35%]	0.804 [chi2 test]
Antibiotics	3 [9%]	4 [24%]	0.124 [chi2 test]
Immunosuppressants	8 [29%]	3 [18%]	0.704 [chi2 test]
Thiopurines	7 [20%]	3 [18%]	0.842 [z test]
Methotrexate	1 [3%]	0 [0%]	0.484 [Z test]
Biologics	16 [46%]	10 [59%]	0.308 [chi2 test]
anti-TNF	15 [43%]	9 [53%]	0.497 [Z test]
anti-α 4β 7	1 [3%]	1 [6%]	0.596 [Z test]
None	6 [17%]	3 [18%]	0.412 [chi2 test]
Data not available	1 [3%]	1 [6%]	0.412 [chi2 test]
Montreal Classification of disease
Age at diagnosis			0.591 [overall chi 2 ]
A1 ≤16 years old	2 [6%]	0 [0%]	0.347 [Z test]
A2 = 17–40 years old	24 [69%]	8 [53%]	0.303 [Z test]
A3 >40 years old	8 [29%]	4 [27%]	0.772 [Z test]
Data not available	1 [3%]	1 [7%]	0.529 [Z test]
Location
L1 Terminal ileum	19 [54%]	N/A	N/A
L2 Colonic	3 [9%]	N/A	N/A
L3 Ileocolic	7 [20%]	N/A	N/A
L4 Upper GI	4 [11%]	N/A	N/A
L1 + L4	1 [3%]	N/A	N/A
E1 proctitis	N/A	1 [7%]	N/A
E2 left-sided colitis	N/A	6 [40%]	N/A
E3 pan-	N/A	8 [53%]	N/A
Data not available	1 [3%]	N/A	N/A
Disease behaviour
B1 non-stricturing, non-penetrating	5 [14%]	N/A	N/A
B2 stricturing	14 [40%]	N/A	N/A
B3 penetrating	15 [43%]	N/A	N/A
P perianal involvement	3 [9%]	N/A	N/A
Data not available	1 [3%]	N/A	N/A

Data are presented as mean ± SE. Bold text indicates statistically significant results. Italicised and underlined text indicates results for overall statistical tests. Biologic medication consists of anti-tumour necrosis factor [TNF] [adalimumab, infliximab, certolizumab, or golimumab] or anti-α ₄β ₇ integrin [vedolimumab] agents.

CD, Crohn’s disease; UC,ulcerative colitis; GI, gastrointestinal; N/A, not available.